Takara Bio Inc.

Takara Bio Inc.

4974.T
Takara Bio Inc.JP flagTokyo Stock Exchange
1,144.00
JPY
+1.00
- -
137.76BMarket Cap

Total Valuation

Takara Bio Inc. carries a market capitalization of 137.76B, placing it among publicly traded companies globally. Its enterprise value stands at 81.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap137.76B
Enterprise Value81.44B

Share Statistics

Takara Bio Inc. currently has 120.42M shares outstanding.

Shares Outstanding120.42M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Takara Bio Inc. trades at a trailing price-to-earnings ratio of 305.72. The price-to-sales ratio is 4.96, and the price-to-book ratio stands at 1.81.

PE Ratio305.72
PS Ratio4.96
PB Ratio1.81
P/TBV Ratio1.13
P/FCF Ratio113.68
P/OCF Ratio-321.99

Enterprise Valuation

On an enterprise value basis, Takara Bio Inc. trades at an EV/EBITDA multiple of 51.16 and an EV/FCF ratio of 76.22. The EV/Sales ratio of 3.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 51.16 provides insight into valuation relative to core operating earnings.

EV / Sales3.34
EV / EBITDA51.16
EV / EBIT51.16
EV / FCF76.22

Financial Position

Takara Bio Inc. maintains a current ratio of 9.51, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.

Current Ratio9.51
Quick Ratio5.96
Debt / EquityN/A
Debt / EBITDAN/A
Interest Coverage144.73

Financial Efficiency

Takara Bio Inc. posts a return on equity of 0.59 and a return on invested capital of 0.45.

Return on Equity (ROE)0.59
Return on Assets (ROA)0.32
Return on Invested Capital (ROIC)0.45
Return on Capital Employed (ROCE)0.57
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.88

Taxes

Over the trailing twelve months, Takara Bio Inc. has paid 854.00M in income taxes, reflecting an effective tax rate of 67.51.

Income Tax854.00M
Effective Tax Rate67.51

Stock Price Statistics

Takara Bio Inc.'s stock has gained approximately 44.0806% over the past 52 weeks. The 50-day moving average sits at 1,142.34, while the 200-day moving average is 981.40.

Beta (5Y)N/A
52-Week Price Change44.0806%
50-Day Moving Average1,142.34
200-Day Moving Average981.40
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Takara Bio Inc. generated 24.39B in revenue and converted that into 396.00M in net income, yielding earnings per share of 3.42. EBITDA reached 1.59B, while operating income came in at 1.59B.

Revenue24.39B
Gross Profit13.57B
Operating Income1.59B
Pretax Income1.27B
Net Income396.00M
EBITDA1.59B
EBIT1.59B
Earnings Per Share (EPS)3.42

Balance Sheet

Total book value stands at 66.90B, with working capital of 57.06B providing operational flexibility.

Cash & Cash Equivalents39.96B
Total DebtN/A
Net Debt-39.96B
Equity (Book Value)66.90B
Book Value Per Share555.92
Working Capital57.06B

Cash Flow

Takara Bio Inc. produced -376.00M in operating cash flow over the past twelve months. After subtracting -1.44B in capital expenditures, free cash flow totaled -1.82B - equivalent to -15.10 per share.

Operating Cash Flow-376.00M
Capital Expenditures-1.44B
Free Cash Flow-1.82B
FCF Per Share-15.10

Margins

Takara Bio Inc. operates with a gross margin of 55.62, reflecting its pricing power and cost economics. The operating margin of 6.53 and net profit margin of 1.62 provide insight into operational efficiency.

Gross Margin55.62
Operating Margin6.53
Pretax Margin5.19
Profit Margin1.62
EBITDA Margin6.53

Dividends & Yields

The company's payout ratio of 1.17 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.04
Dividend YieldN/A
Payout Ratio1.17
Shareholder Yield0.09
FCF Yield0.88

Stock Splits

Takara Bio Inc.'s most recent stock split took place on March 29, 2011 with a 1:400 split ratio.

Last Split Date3/29/2011
Split Ratio1:400

Scores

Takara Bio Inc. posts an Altman Z-Score of 9.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.42